Exciting news from the USA, where Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, has launched an enhanced blood test for detecting gluten sensitivity which may in the future help to do away with the need for intestinal biopsies.
The Cyrex Array 3 Wheat/Gluten Proteome Reactivity and Autoimmunity test panel is the only wheat/gluten panel that assesses three antigen triggers of disorders (gluten proteins, opioid peptides and tissue binding isolates), and was developed to differentiate between the coeliac manifestation and the non-coeliac gluten sensitivity.
“Array 3 alone cannot be used to diagnose coeliac disease,” explains Jama Lambert, Director of Education at Cyrex Laboratories. “Rather, it is a clinical tool the doctor can use—along with other pertinent clinical information—to reach a diagnosis. Assuming the patient maintains a regular diet that includes wheat/gluten, Array 3 will detect gluten/wheat reactivity and autoimmunity because it accurately identifies gluten reactivity and measures antibody production against 8 wheat proteins and peptides, three essential enzymes (transglutaminase-2, transglutaminase-3 and transglutaminase-6), and the gliadin transglutaminase complex.”
The test will hopefully help to increase the accuracy of diagnoses. “Based on articles published in scientific journals, an astounding 50 percent of patients diagnosed with coeliac disease receive a false negative test result when measuring only Deamidated Alpha Gliadin-33-mer antibody,” says Dr Aristo Vojdani, pioneer of ELISA food reactivity testing and chief scientific advisor for Cyrex Laboratories. “This is problematic because these gluten-reactive patients, who do not respond to alpha-gliadin-33-mer, instead may react to one or more of the other gluten proteins that are not being measured by other testing panels. This problem is exactly why Array 3 was developed.”
Array 3 is recommended for patients who have non-responsive GI symptoms, present with multiple-symptom complaints (including joint pain, fatigue, muscle pain, brain fog, hormone imbalances and chronic inflammation), and suffer from depression or neurodegenerative symptoms like peripheral neuropathy, Alzheimer’s disease, or multiple sclerosis.
“The Array 3 test panel is the most accurate test available for gluten reactivity,” says Jama Lambert. “To diagnose coeliac disease, one must prove total villous atrophy—which can only be done by biopsy. Array 3 provides a practitioner with enough information that can be used in conjunction with other pertinent clinical information, that differentiation between potential coeliac disease and non-coeliac gluten sensitivity is possible. If the results look like possible coeliac disease, the practitioner can refer the patient for biopsy to obtain an official coeliac disease diagnosis.”
It is possible that Array 3 might do away with the intestinal biopsy needed to confirm coeliac disease, but this is still someway off. Jama Lambert continues: “Researchers out of Israel have argued that antibodies to the Gliadin-Transglutaminase Complex, available on Array 3, is such a strong biomarker of intestinal damage that biopsies are no longer necessary. These researchers have not made headway in changing the official workup for the diagnosis of Coeliac disease but it is possible that in the future Array 3 will be allowed to replace biopsies.”
Cyrex says it is in the process of expansion internationally, with Australia high on the priority list. The test is already available in to UK and Ireland residents, but the request must come via a healthcare professional. “Regenerus Labs is Cyrex's Logistics and Marketing Partner set up in the UK and Ireland to fulfill orders from HCPs and will work with them to get the Array 3 test performed. Healthcare professionals should contact Regenerus Labs for all UK and Ireland inquiries.”